The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...

Consultant Dr Kulkarni carried out a range of tests, which, over the following months, revealed Harmony had tracheomalacia ...

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for ...

Electromed Inc (ELMD) achieves record revenues and net income while navigating increased expenses and competitive pressures.

The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...